In the USP32 high-expression group, the activation of lymphocyte-mediated immune responses has been demonstrated to play a pivotal role in the regulation of inflammation and the dysregulation of the cell cycle in patients with PAH. Here, USP32 is linked to pulmonary arterial hypertension.